These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 12769711)
21. [Development of farsenyl transferase inhibitors as anticancer agents]. Cestac P; Doisneau-Sixou S; Favre G Ann Pharm Fr; 2005 Jan; 63(1):76-84. PubMed ID: 15803104 [TBL] [Abstract][Full Text] [Related]
22. Farnesyltransferase inhibitors as anticancer agents: current status. Zhu K; Hamilton AD; Sebti SM Curr Opin Investig Drugs; 2003 Dec; 4(12):1428-35. PubMed ID: 14763128 [TBL] [Abstract][Full Text] [Related]
23. Analogues of 1-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo-[5,6]-cyclohepta [1,2-b]pyridin-11-yl)piperidine as inhibitors of farnesyl protein transferase. Afonso A; Weinstein J; Kelly J; Wolin R; Rosenblum SB; Connolly M; Guzi T; James L; Carr D; Patton R; Bishop WR; Kirshmeier P; Liu M; Heimark L; Chen KJ; Nomeir AA Bioorg Med Chem; 1999 Sep; 7(9):1845-55. PubMed ID: 10530932 [TBL] [Abstract][Full Text] [Related]
24. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras. Brassard DL; English JM; Malkowski M; Kirschmeier P; Nagabhushan TL; Bishop WR Exp Cell Res; 2002 Feb; 273(2):138-46. PubMed ID: 11822869 [TBL] [Abstract][Full Text] [Related]
25. Mass spectrometric studies of potent inhibitors of farnesyl protein transferase--detection of pentameric noncovalent complexes. Mirza UA; Chen G; Liu YH; Doll RJ; Girijavallabhan VM; Ganguly AK; Pramanik BN J Mass Spectrom; 2008 Oct; 43(10):1393-401. PubMed ID: 18438977 [TBL] [Abstract][Full Text] [Related]
26. Identification of pharmacokinetically stable 3, 10-dibromo-8-chlorobenzocycloheptapyridine farnesyl protein transferase inhibitors with potent enzyme and cellular activities. Taveras AG; Deskus J; Chao J; Vaccaro CJ; Njoroge FG; Vibulbhan B; Pinto P; Remiszewski S; del Rosario J; Doll RJ; Alvarez C; Lalwani T; Mallams AK; Rossman RR; Afonso A; Girijavallabhan VM; Ganguly AK; Pramanik B; Heimark L; Bishop WR; Wang L; Kirschmeier P; James L; Carr D; Liu M J Med Chem; 1999 Jul; 42(14):2651-61. PubMed ID: 10411485 [TBL] [Abstract][Full Text] [Related]
27. Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas. Dempke WC Anticancer Res; 2003; 23(2A):813-8. PubMed ID: 12820305 [TBL] [Abstract][Full Text] [Related]
28. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice. Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541 [TBL] [Abstract][Full Text] [Related]
29. Preclinical and clinical evaluation of farnesyltransferase inhibitors. Baum C; Kirschmeier P Curr Oncol Rep; 2003 Mar; 5(2):99-107. PubMed ID: 12583826 [TBL] [Abstract][Full Text] [Related]
30. Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units. Petit T; Izbicka E; Lawrence RA; Bishop WR; Weitman S; Von Hoff DD Ann Oncol; 1999 Apr; 10(4):449-53. PubMed ID: 10370788 [TBL] [Abstract][Full Text] [Related]
31. Farnesyl transferase inhibitors as anticancer agents. Haluska P; Dy GK; Adjei AA Eur J Cancer; 2002 Sep; 38(13):1685-700. PubMed ID: 12175684 [TBL] [Abstract][Full Text] [Related]
32. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies. Sebti SM; Hamilton AD Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643 [TBL] [Abstract][Full Text] [Related]
33. CA1A2X-competitive inhibitors of farnesyltransferase as anti-cancer agents. Omer CA; Kohl NE Trends Pharmacol Sci; 1997 Nov; 18(11):437-44. PubMed ID: 9426472 [TBL] [Abstract][Full Text] [Related]
34. Farnesyl protein transferase inhibitor ZARNESTRA R115777 - history of a discovery. Venet M; End D; Angibaud P Curr Top Med Chem; 2003; 3(10):1095-102. PubMed ID: 12769710 [TBL] [Abstract][Full Text] [Related]
35. Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models. Liu M; Bishop WR; Nielsen LL; Bryant MS; Kirschmeier P Methods Enzymol; 2001; 333():306-18. PubMed ID: 11400347 [TBL] [Abstract][Full Text] [Related]
36. Farnesyl transferase inhibitors: the next targeted therapies for breast cancer? O'Regan RM; Khuri FR Endocr Relat Cancer; 2004 Jun; 11(2):191-205. PubMed ID: 15163298 [TBL] [Abstract][Full Text] [Related]
37. Development of farnesyl transferase inhibitors: a review. Appels NM; Beijnen JH; Schellens JH Oncologist; 2005 Sep; 10(8):565-78. PubMed ID: 16177281 [TBL] [Abstract][Full Text] [Related]
38. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Smalley KS; Eisen TG Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674 [TBL] [Abstract][Full Text] [Related]